SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-6.32%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$742M
AUM Growth
+$742M
(-26%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-24.03%
Top 10 Holdings %
Top 10 Hldgs %
99.97%
Holding
11
New
–
Increased
2
Reduced
2
Closed
–
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$15.2M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$5.09M |
Top Sells
| 1 |
Alkermes
ALKS
|
$196M |
| 2 |
Mersana Therapeutics
MRSN
|
$2.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $197M | 26.57% | 7,042,200 -6,997,800 | -50% | -$196M |
|
2
Biogen
BIIB
$19.4B
| $165M | 22.26% | 643,000 | – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $158M | 21.26% | 16,390,000 | – | – |
|
4
Innoviva
INVA
$1.29B
| $94.5M | 12.73% | 7,277,000 | – | – |
|
5
Gilead Sciences
GILD
$140B
| $69M | 9.29% | 920,400 | – | – |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $41.2M | 5.55% | 366,000 +134,700 | +58% | +$15.2M |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $9.61M | 1.29% | 10,442,453 +5,532,453 | +113% | +$5.09M |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.49M | 0.74% | 775,000 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $1.31M | 0.18% | 618,000 | – | – |
|
|
10
Mersana Therapeutics
MRSN
$36.5M
| $699K | 0.09% | 550,000 -2,082,900 | -79% | -$2.65M |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $254K | 0.03% | 185,183 | – | – |
|